Screening patients with lung cancer using low-dose computed tomography (LDCT) has been associated with reducing lung cancer mortality as much as 20%, but the technique remains limited.
Researchers also found differences in the composition of the gut microbiome between patients with lung cancer who experienced toxicity and those who did not.
Researchers found that IMP2, a cancer autoantibody, was significantly associated with time to progression in patients with NSCLC treatment with non-frontline PD-1/PD-L1.
Researched conducted a post hoc pooled analysis of 3 KEYNOTE cohorts and found the addition of pembrolizumab improved OS and PFS in patients with NSCLC.